'%2F%3E%3Cpath%20d%3D'M11%205H21M13.5%205V11.6A8.5%208.5%200%201%200%2018.5%2011.6V5'%20fill%3D'none'%20stroke%3D'%23fff'%20stroke-width%3D'3.4'%20stroke-linecap%3D'round'%20stroke-linejoin%3D'round'%2F%3E%3Cpath%20d%3D'M10.6%2019.6L13.9%2021.8L17.6%2018.4L21.4%2020.4'%20fill%3D'none'%20stroke%3D'%23fff'%20stroke-width%3D'2.6'%20stroke-linecap%3D'round'%20stroke-linejoin%3D'round'%2F%3E%3Ccircle%20cx%3D'17.6'%20cy%3D'18.4'%20r%3D'2.6'%20fill%3D'%23fff'%2F%3E%3C%2Fsvg%3E){kind=small}
Morepen Laboratories Limited
MOREPENLAB (NSE) · MOREPENLAB (BSE 500288) · ISIN INE083A01026 · Pharmaceuticals · Est. 1984 · listed 1999 · website
ASM Long term Stage 4 · BSE ASM Long term Stage 4 · NSE
In Q1 FY27 (quarter to 30 June 2026, standalone), revenue was ₹541.04 cr and profit after tax ₹54 cr. Revenue was 38.3% higher than in Q1 FY26.
Next: Board meeting: financial results on 27 October 2026.
Open the full company file Every section, filings and your notes, in the app.
Quarterly results
| Quarter | Revenue | Profit after tax | EPS (₹) | Filed |
|---|---|---|---|---|
| Q1 FY27 standalone | ₹541.04 cr | ₹54 cr | 0.99 | 4 Aug 2026 |
| Q4 FY26 standalone | ₹462.81 cr | ₹20.12 cr | 0.37 | 26 May 2026 |
| Q3 FY26 standalone | ₹457.57 cr | ₹23.5 cr | 0.43 | 10 Feb 2026 |
| Q2 FY26 standalone | ₹369.53 cr | ₹14.38 cr | 0.26 | 14 Nov 2025 |
| Q1 FY26 standalone | ₹391.28 cr | ₹8.06 cr | 0.15 | 6 Aug 2025 |
| Q4 FY25 standalone | ₹381.94 cr | ₹11.91 cr | 0.20 | 12 May 2025 |
Balance sheet
| As of | Total equity | Borrowings | Total assets |
|---|---|---|---|
| 31 Mar 2026 standalone | ₹1,242.76 cr | ₹193.59 cr | ₹1,907.66 cr |
| 30 Sep 2025 standalone | ₹1,192.49 cr | ₹145.24 cr | ₹1,709.69 cr |
| 31 Mar 2025 standalone | ₹1,181.5 cr | ₹78.96 cr | ₹1,721.2 cr |
Shareholding
| Promoter | FII | DII | Public |
|---|---|---|---|
| 35.65% | 3.43% | 1.71% | 64.35% |
Latest filings
- Annual Report FY2025-26 (New) 2 September 2026 · NSE
- Morepen Laboratories Limited has informed the Exchange regarding a press release dated August 04, 2026, titled "Morepen clocks highest-ever quarterly revenue and earnings in Q1 FY27; EBITDA grows by 2 4 August 2026 · NSE
- Morepen Laboratories Limited has informed the Exchange about Investor Presentation 4 August 2026 · NSE
- Morepen Laboratories Limited has submitted to the Exchange, the financial results for the period ended Jun 30, 2026. 4 August 2026 · NSE
- Morepen Laboratories Limited has informed the Exchange about Investor Presentation 27 May 2026 · NSE
Other companies in Pharmaceuticals
- Lupin Limited
- Sun Pharmaceutical Industries Limited
- Torrent Pharmaceuticals Limited
- Zydus Lifesciences Limited
- Ajanta Pharma Limited
- Alivus Life Sciences Limited
- Wockhardt Limited
- Indoco Remedies Limited
Figures as filed by the company with NSE and BSE; surveillance status from the exchanges' lists. Updated 30 September 2026.
Information and calculation tools by Rachid Asen. Not investment advice or research. Facts from company filings and the exchanges' lists, for information only; not a recommendation to buy, sell or hold. Verify with the exchange.